HER2

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford

DDW Highlights: 7 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More

#Podcasts

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Gene therapy #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford #University of Queensland

This week in Drug Discovery (29 June – 3 July) 

News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW.  This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.  The… Read More

#News

Patient having a mammogram
#Breast cancer #HER2

Breast cancer patients profiled to determine drug efficacy  

Researchers have identified which breast cancer patients should be treated with anthracyclines and who can safely avoid side effects of the drugs, a study shows.  Scientists from precision oncology company Agendia published a paper in JCO Precision Oncology, which demonstrates HER2-negative (HR+HER2-) early-stage breast cancer (EBC) patients are most… Read More

#Cancer Research #News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Cancer cells
#Biomarkers #Breast cancer #Genetic profiling #HER2

Genetic markers drive breast cancer drug resistance, study shows 

Researchers have made a groundbreaking discovery into why some forms of breast cancer are drug resistant.  Cancer scientists at City St George’s, University of London found a ‘molecular signature’ drives drug resistance in an aggressive type of breast cancer known as HER2-positive breast cancer.  The… Read More

#Cancer Research #News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

New episode: DDW Highlights 19 June

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs,… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

This week in drug discovery (12-16 June)  

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation… Read More

#News

Cancer cells
#American Society of Clinical Oncology #Breast cancer #Cancer research #HER2 #Oncology #The College of American Pathologists

Updates to HER2 testing guidelines reduces confusion 

The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) have reaffirmed the Human Epidermal Growth Factor Receptor 2 (HER2) Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results.  The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that… Read More

#Cancer Research #News #Regulatory #Trending News

Mammography
#Breast cancer #Cancer research #European Commission #Gene mutation #Genetics / genomes #HER2 #Oncology

Drug approved for breast cancer with low levels of HER2 expression

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer.  The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six… Read More

#Cancer Research #Editor's Choice #News

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cell and gene therapy #Cell therapy #HER2 #Immunotherapy #Oncology #Precision medicine #T-Cells #Tumours

Positive interim data for cell therapy in solid tumours

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More

#Cancer Research #News